Laura Friedman held the second meeting of her LGBTQ Advisory Committee this week, which is the kind of constituent-service story that earns a press release and a warm photo op. But Blind Trust tracks a different kind of record: the one in the disclosure filings. On that front, Friedman's 90-day ledger is three trades deep, one of them scoreable, and that one is underwater by a margin that would make any retail investor wince.
Advisory Panels and Angry Constituents
Friedman's office announced the second convening of her LGBTQ Advisory Committee, framing it as outreach and representation — the kind of move a freshman member makes to signal she's listening.
The Bluesky conversation around her name is less warm. Constituents are tagging her alongside Adam Schiff and Alex Padilla to register frustration with the California Democratic delegation broadly. Others are surfacing her AIPAC endorsement and the reported $600,000-plus her campaign raised, noting the tension between that donor profile and a progressive district. Four posts is not a groundswell, but the temperature in her mentions runs hotter than a committee press release would suggest.
Here's what the financial filings add.
Three Trades. One Score. It's Not Pretty.
In the last 90 days, Friedman has disclosed three transactions. The full record is on Blind Trust. The short version:
- March 24, 2026: Exchange of Abbott Laboratories (ABT), $1,000–$15,000 range.
- April 8, 2026: Exchange of Hologic (HOLX), $1,000–$15,000 range.
- April 8, 2026: Sale of Hologic (HOLX), $1,000–$15,000 range.
Congress's disclosure ranges are famously broad. "$1,000–$15,000" is a window wide enough to drive a bus through, so parsing the exact dollar exposure here is an exercise in frustration. What we can say: the positions are small by congressional standards, the tickers are healthcare names, and on the one trade Blind Trust has been able to score, the outcome is a 30-day alpha of negative 15.9 percent versus the S&P 500.
One scored trade. Zero positive outcomes. Mean alpha: minus 15.9 percent.
One scored trade is one scored trade. You can't build a thesis about trading skill from a single data point. What you can say is that the one number we have is ugly, and the sample has nowhere to go but up from here.
What Hologic and Abbott Have to Do With Her Committees
Friedman sits on the House Committee on Transportation and Infrastructure — highways, railroads, water resources, emergency management — and the House Committee on Science, Space, and Technology, covering the Energy subcommittee.
Hologic makes medical devices, diagnostics, and women's health products. Abbott Laboratories is a diversified healthcare and medical devices conglomerate. Neither sector sits anywhere near Transportation and Infrastructure or Science, Space, and Technology.
These are healthcare trades from a member who does not sit on a committee with healthcare jurisdiction. No overlap to flag, no remit to cross-reference. A congresswoman holding Abbott and Hologic is not obviously different from any other individual holding the same names. The trades are disclosed and sitting in the public record. The committee map simply doesn't connect them to an oversight angle.
The Floor Votes: Banking Bills and a Surveillance Nay
Friedman's recent floor votes are worth noting, with the same caveat: floor votes outside a member's committee jurisdiction are just votes. They don't imply special insight or oversight leverage.
On May 20, she voted Yea on four bills in a single session: the American Access to Banking Act, the Community Bank Deposit Access Act of 2025, the Keeping Deposits Local Act, and the 25th Anniversary of 9/11 Commemorative Coin Act. The first three are banking and deposit-access legislation. Friedman doesn't sit on Financial Services and carries no disclosed bank-sector holdings in the 90-day window.
On June 11, she voted Nay on a FISA reauthorization bill (H.R. 9238) that ultimately failed. On May 21, she voted Nay on the Veterans 2nd Amendment Protection Act and the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act, both of which passed without her support. None of those votes connect to her disclosed holdings or committee assignments in any combination that warrants further scrutiny.
The vote-trade overlap table for Friedman is empty. No flagged timing collisions between her trades and her votes in this window.
A Thin File With Nothing Hidden In It
Three small trades, fully disclosed, in sectors outside her committee jurisdiction, with a losing alpha record that suggests no particular informational edge. The structural critique here is broader than Friedman: members are required to disclose within 45 days of a transaction, but they are not required to divest, recuse, or justify why a healthcare position sits in the portfolio of someone who oversees railroads and water resources. Disclosure is the whole mechanism.
Friedman's constituents tagging her on Bluesky are frustrated about things that have nothing to do with Abbott Laboratories. The AIPAC money and the progressive-district tension are political questions the filings don't answer. What the filings answer is narrower: what she traded, when, and in what size range. Small healthcare names, in March and April, at amounts that don't crack the five-figure ceiling. The one scored result is down 15.9 points against the market.
What to Watch
The HOLX trades from April 8 haven't been scored yet in the available data. An exchange and a same-day sale of Hologic on the same date is a slightly unusual combination worth watching when the 30-day window closes. Hologic's business is squarely in women's health diagnostics, a sector with non-trivial legislative exposure in the current Congress. Friedman has no committee jurisdiction there — but the result matters when it lands.
Her full disclosure record, including any future filings, is tracked in real time on Blind Trust. Three trades in 90 days is a light quarter. That can change.
The receipts are public. Make of them what you make of them.